Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Levels of and Changes in Childhood Body Mass Index in Relation to Risk of Atrial Fibrillation and Atrial Flutter in Adulthood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Infertility in a Cohort of Male Danish Firefighters: A Register-Based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. ASSOCIATIONS OF OCCUPANT MOTOR VEHICLE CRASH WITH FUTURE HEART FAILURE AND ISCHEMIC STROKE IN OLDER ADULTS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effect estimates in randomized trials and observational studies: comparing apples with apples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Mortality in women treated with assisted reproductive technology treatment - addressing the healthy patient effect

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Whole genome sequencing of breast cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Thomas P Ahern
  • Daniel L Hertz
  • Per Damkier
  • Bent Ejlertsen
  • Stephen J Hamilton-Dutoit
  • James M Rae
  • Meredith M Regan
  • Alastair M Thompson
  • Timothy L Lash
  • Deirdre P Cronin-Fenton
Vis graf over relationer

Tamoxifen therapy for estrogen receptor-positive breast cancer reduces the risk of recurrence by approximately one-half. Cytochrome P-450 2D6, encoded by the polymorphic cytochrome P-450 2D6 gene (CYP2D6), oxidizes tamoxifen to its most active metabolites. Steady-state concentrations of endoxifen (4-hydroxy-N-desmethyltamoxifen), the most potent antiestrogenic metabolite, are reduced in women whose CYP2D6 genotypes confer poor enzyme function. Thirty-one studies of the association of CYP2D6 genotype with breast cancer survival have yielded heterogeneous results. Some influential studies genotyped DNA from tumor-infiltrated tissues, and their results may have been susceptible to germline genotype misclassification from loss of heterozygosity at the CYP2D6 locus. We systematically reviewed 6 studies of concordance between genotypes obtained from paired nonneoplastic and breast tumor-infiltrated tissues, all of which showed excellent CYP2D6 genotype agreement. We applied these concordance data to a quantitative bias analysis of the subset of the 31 studies that were based on genotypes from tumor-infiltrated tissue to examine whether genotyping errors substantially biased estimates of association. The bias analysis showed negligible bias by discordant genotypes. Summary estimates of association, with or without bias adjustment, indicated no clinically important association between CYP2D6 genotype and breast cancer survival in tamoxifen-treated women.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Epidemiology
Vol/bind185
Udgave nummer2
Sider (fra-til)75-85
Antal sider11
ISSN0002-9262
DOI
StatusUdgivet - 15 jan. 2017

ID: 52152551